Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients

Objectives: Although methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA), patients experience clinical resistance to MTX upon prolonged treatment. We explored whether new-generation antifolates elicit superior anti-inflammatory properties when compared to MTX, based on their capacity to inhibit tumour necrosis factor (TNF)-α production. Method: T cells in whole blood from 18 RA patients (including MTX-naïve, MTX- responsive, and MTX non-responsive patients) and seven healthy volunteers were stimulated with αCD3/αCD28 antibodies and incubated ex vivo for 72 h with MTX and eight novel antifolate drugs with potentially favourable biochemical and pharmacological properties. Drug concentrations exerting 50% inhibition (IC-50) of TNF-α production (by enzyme-linked immunosorbent assay, ELISA) were determined as an estimate for their anti-inflammatory capacity. In addition, induction of T-cell apoptosis was evaluated by flow cytometry. Results: The new-generation antifolates PT523, PT644, raltitrexed, and GW1843 proved to be potent inhibitors of TNF-α production in activated T cells from all three groups of RA patients and from healthy volunteers. Based on IC-50 values, these antifolates were up to 10.3 times more potent than MTX. The anti-inflammatory effects were observed at drug concentrations that provoked suppression of T-cell activation and induction of apoptosis in 20–40% of activated T cells. Conclusion: In an ex-vivo setting, novel antifolates elicited marked inhibition of TNF-α production in activated T cells from RA patients. Further clinical evaluation is warranted to investigate whether a low dosage of these antifolates can elicit immunosuppressive effects equivalent to MTX, and whether they are superior to MTX in patients who fail to respond to MTX.

[1]  P. Casey,et al.  Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Wolfe.  The epidemiology of drug treatment failure in rheumatoid arthritis. , 1995, Bailliere's clinical rheumatology.

[3]  P. van Riel,et al.  Methotrexate modulates the kinetics of adenosine in humans in vivo , 2005, Annals of the rheumatic diseases.

[4]  B. Aggarwal,et al.  Methotrexate Suppresses NF-κB Activation Through Inhibition of IκBα Phosphorylation and Degradation1 , 2001, The Journal of Immunology.

[5]  R. Straub,et al.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[6]  Link,et al.  Inhibition of cytokine production by methotrexate . Studies in healthy volunteers and patients with rheumatoid arthritis , 2007 .

[7]  L. Matherly,et al.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues , 2009, Expert Reviews in Molecular Medicine.

[8]  N. Zurgil,et al.  Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines , 2005, Inflammation Research.

[9]  Yehuda G Assaraf,et al.  Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  B. Dijkmans,et al.  Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside , 2007, Nature Clinical Practice Rheumatology.

[11]  G. Peters,et al.  Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay , 1999 .

[12]  B. Aggarwal,et al.  Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. , 2001, Journal of immunology.

[13]  B. Cronstein,et al.  Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. , 2003, Arthritis and rheumatism.

[14]  I. Goldman,et al.  Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. , 2001, Biochemical pharmacology.

[15]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[16]  A. Rosowsky,et al.  Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor Nα-(4-Amino-4-deoxypteroyl)-Nδ-hemiphthaloyl-l-ornithine (PT523) , 1998 .

[17]  N. Olsen,et al.  Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. , 2012, Arthritis and rheumatism.

[18]  Jerzy Swierkot,et al.  Methotrexate in rheumatoid arthritis. , 2006, Pharmacological reports : PR.

[19]  M. Romero,et al.  Targeting the Proton-Coupled Folate Transporter for Selective Delivery of 6-Substituted Pyrrolo[2,3-d]Pyrimidine Antifolate Inhibitors of De Novo Purine Biosynthesis in the Chemotherapy of Solid Tumors , 2010, Molecular Pharmacology.

[20]  I. Rosenberg,et al.  Preliminary Evidence Shows That Folic Acid Fortification of the Food Supply Is Associated with Higher Methotrexate Dosing in Patients with Rheumatoid Arthritis , 2007, Journal of the American College of Nutrition.

[21]  L. Genestier,et al.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. , 1998, The Journal of clinical investigation.

[22]  B. Kirschbaum,et al.  Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? , 1999, The Biochemical journal.

[23]  A. Rosowsky,et al.  Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. , 1994, Molecular pharmacology.

[24]  E. Howland,et al.  AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase , 2004, Investigational New Drugs.

[25]  R. Hughes,et al.  Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. , 2003, Rheumatology.

[26]  J. Kremer.  Toward a better understanding of methotrexate. , 2004, Arthritis and rheumatism.

[27]  G. Peters,et al.  Classification Of Ex Vivo Methotrexate Resistance In Acute Lymphoblastic and Myeloid Leukaemia , 2000, British journal of haematology.

[28]  G. Jansen,et al.  Folate homeostasis and antiproliferative activity of folates and antifolates. , 2001, Nutrition.

[29]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[30]  B. Cronstein,et al.  Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.

[31]  G. Peters,et al.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.

[32]  Ph.D Jackie Walling MBChB.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates , 2005, Investigational New Drugs.

[33]  G. Peters,et al.  Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. , 1999, Molecular pharmacology.

[34]  T. Nakamura,et al.  Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[35]  M. Waltham,et al.  Intrinsic and acquired resistance to methotrexate in acute leukemia. , 1996, The New England journal of medicine.

[36]  G. Aherne,et al.  Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Akabas,et al.  Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary Folate Malabsorption , 2006, Cell.

[38]  O. Castañeda,et al.  Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. , 2006, The Journal of rheumatology.

[39]  B. Dijkmans,et al.  Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. , 2009, Arthritis and rheumatism.

[40]  K. Izeradjene,et al.  Mechanisms of action of methotrexate. , 2000, Immunopharmacology.

[41]  N. Olsen,et al.  Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. , 2011, Arthritis and rheumatism.

[42]  L. Criswell,et al.  Primary Sjögren's syndrome as a systemic disease: A study of participants enrolled in an International Sjögren's syndrome registry , 2012, Arthritis care & research.

[43]  J. Świerkot,et al.  Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate , 2004, Annals of the rheumatic diseases.

[44]  G. Peters,et al.  Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. , 1995, Molecular pharmacology.

[45]  B. Dijkmans,et al.  Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. , 2009, Arthritis and rheumatism.

[46]  K. Woollard,et al.  The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species , 2003, British journal of pharmacology.

[47]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[48]  G. Peters,et al.  A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance* , 1998, The Journal of Biological Chemistry.

[49]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[50]  J. Bertino,et al.  Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.